01 — At a Glance
The Narrative vs. The Numbers: A Story In Two Acts
- 52-Week High / Low₹125 / ₹32.9
- Q3 FY26 Revenue₹101 Cr
- Q3 FY26 PAT₹19.2 Cr
- TTM EPS₹0.61
- Annualised EPS (Q3 Avg × 4)₹1.20
- Book Value / Share₹5.55
- Price to Book6.09x
- Operating CF (FY25)-₹87 Cr
- Working Capital Days40 days
- Total Assets (Sep 2025)₹468 Cr
Flash Summary: Fischer Medical just delivered Q3 FY26 PAT of ₹19.2 crore — up 6,731% YoY from ₹0.3 crore. Revenue jumped 760% to ₹101 crore. The story is slick: proprietary MRI tech, FDA approvals, government contracts, global expansion. But the stock crashed 74% from peak (₹125 → ₹32.9). Operating cash flow is negative ₹87 crore. The Company Secretary just resigned. Working capital cycles are suspiciously tight. P/E is 55.3x. ROE is 0.70%. Something doesn’t add up — and the market has noticed.
02 — Introduction
On Paper, A Healthcare Unicorn. In Practice, A Working Capital Treadmill.
Fischer Medical Ventures started as a nothing—literally incorporated in 1993 as a laboratory chemicals trader generating close to zero revenue for three decades. Then something shifted. Around 2023-24, the company pivoted hard. It partnered with (or acquired) Time Medical Systems, a Singapore-based MRI manufacturer with 20+ years of R&D and partnerships with Columbia University and Harvard Medical School. Suddenly, revenue started flowing. From ₹0 in Mar 2023 to ₹21 Cr (Mar 2024) to ₹111 Cr (Mar 2025) to ₹260 Cr TTM. That’s growth on steroids.
The investor presentation reads like a Silicon Valley fever dream: proprietary permanent-magnet MRI technology, helium-free superconductor systems, CDSCO-approved devices, FDA clearances, AI-powered diagnostic kiosks (FlynnCare), global partnerships in Indonesia, Philippines, Malaysia, and Singapore. The team includes ex-Harvard researchers, ex-GE executives, and government luminaries (ex-Malaysian Health Minister, ex-Philippine Governor). Order books exceed ₹100 crore. Government tenders are being won. The vision is compelling: decentralize and democratize healthcare diagnostics across emerging markets.
Then you look at the actual financials. Operating cash flow: -₹87 crore in FY25 despite ₹111 crore revenue. Working capital compression from 498 days to 40 days (suspiciously fast). Debtors at 251 days (government customers paying slowly). Borrowings jumped from ₹2 Cr to ₹85 Cr to ₹30 Cr (erratic). A ₹40 crore HDFC Bank loan with shares pledged (January 2026). Company Secretary resigned. Stock crashed 70% in six months despite “record quarters.” P/E at 55.3x while ROE is 0.70%. The market is asking: Is this real revenue or accounting timing? Real growth or a capital-raise treadmill?
The Core Question: Is Fischer Medical a transformational healthcare infrastructure play that the market is temporarily panicking about? Or is it a company on a financing treadmill, booking revenue on extended credit terms to government customers, and masking negative cash flow with shareholder dilution?
03 — Business Model: WTF Do They Actually Do?
Diagnosis Devices + Health Screening Kiosks + Digital Platforms = Chaos Or Genius?
Fischer Medical operates in three distinct business lines, and honestly, that’s part of the confusion.
Line 1: Diagnostic Imaging (Hardware) — The company designs and manufactures medical imaging devices. The flagship is MICA, a 1.5T whole-body MRI system with proprietary permanent-magnet technology (saves helium, reduces operating costs by 20-25%, CDSCO-approved). They also have PICA (0.35T open MRI, FDA-approved), NOVA (1.5T brain imaging), QUIN (1.5T helium-free). Then CT scans (CT 16, CT 64, CT 124) and handheld AI X-rays. These are high-ticket items (₹1–₹3 crore per unit), sold primarily to hospitals and diagnostic chains.
Line 2: Health Screening Kiosks (FlynnCare) — The company deploys diagnostic kiosks in schools, rural health units, and community centers. These kiosks run AI-powered health screenings (vitals, ECG, fundus imaging, breast screening, TB detection, etc.), generate instant reports, and feed data to a cloud platform (MIDAS, ATLAS, LIVE Dx). This is a recurring revenue model (software subscriptions, per-screening fees). It’s lower-ticket, high-volume, high-margin. The concall mentions deployments across India, Indonesia, Philippines, Singapore.
Line 3: Digital Health Platforms — The company offers EHR, HIS, tele-diagnosis, and practice management software. These platforms are embedded into hospital systems and used for remote consultations and data analytics. Recurring revenue, high margins, but requires deep integration work.
The business model is genuinely compelling: bundle hardware (MRI, X-ray, CT) with software (FlynnCare kiosks, MIDAS platform) and charge governments for integrated diagnostic infrastructure at scale. India needs ₹20+ lakh crore in diagnostic capex over the next decade. Fischer Medical is right to be ambitious. The problem: the company is burning cash to scale all three simultaneously, mostly on credit terms to government customers who pay 90+ days later.
Concall Insight (Nov-Dec 2025): Management emphasized that FlynnCare deployments are accelerating (schools in India, rural units in Indonesia, Philippines). They mentioned “strong order books” and “pilot projects converting to tenders.” But they didn’t address why operating cash flow is so negative, or how they’re funding growth without consistent capital raises.
04 — Financials Overview
Q3 FY26: Revenue Exploded. Cash Burned. Stock Crashed.
Result type: Quarterly Results | Q3 FY26 EPS: ₹0.30 | Q1 FY26 EPS: ₹0.08, Q2 FY26 EPS: ₹0.21, Q3 FY26 EPS: ₹0.30 | Annualised EPS (Average Q1–Q3 × 4): (₹0.08+₹0.21+₹0.30)/3 × 4 = ₹1.97
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 101 | 12.5 | 86 | +760% | +17.4% |
| Operating Profit | 22 | 0 | 16 | N/A | +37.5% |
| Operating Margin % | 21% | 3% | 19% | +1800 bps | +200 bps |
| Net Profit | 19.2 | 0.3 | 14 | +6,731% | +37% |
| EPS (₹) | 0.30 | -0.01 | 0.21 | N/A | +43% |
The Honest Take: Yes, revenue is growing (760% YoY is real). Yes, margins are improving (21% operating margin is solid for medtech). But the 6,731% profit growth is misleading. Why? Because Q3 FY25 profit was ₹0.3 crore (basically break-even). A small base × big growth = eye-popping percentage. The real story: operating margins went from 3% (Q3 FY25) to 21% (Q3 FY26). That’s expansion. But it’s built on a product mix shift toward higher-margin MRI and X-ray sales, not operational leverage. One bad quarter (fewer device sales), and margins collapse.
💬 Q3 operating margin hit 21%, but FY25 full-year net profit was only ₹1 crore on ₹111 crore revenue (0.9% margin). How do you explain that 20x jump in just one quarter? Is the mix really shifting that fast, or is something else going on?
05 — Valuation: Fair Value Range
Three Methods. Three Different Answers. All Below Current Price.
